PARD has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PARD has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Poniard Pharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in Sep. 2011 was $-2.40. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2011 was $-12.00.
Poniard Pharmaceuticals's EPS (Diluted) for the three months ended in Sep. 2011 was $-2.40. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2011 was $-12.00.
Poniard Pharmaceuticals's EPS without NRI for the three months ended in Sep. 2011 was $-2.40. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2011 was -12.00.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
The historical data trend for Poniard Pharmaceuticals's EPS (Basic) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Poniard Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec01 | Dec02 | Dec03 | Dec04 | Dec05 | Dec06 | Dec07 | Dec08 | Dec09 | Dec10 | |||||||||||
EPS (Basic) | Get a 7-Day Free Trial | -54.80 | -43.20 | -56.40 | -52.40 | -26.40 |
Poniard Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec06 | Mar07 | Jun07 | Sep07 | Dec07 | Mar08 | Jun08 | Sep08 | Dec08 | Mar09 | Jun09 | Sep09 | Dec09 | Mar10 | Jun10 | Sep10 | Dec10 | Mar11 | Jun11 | Sep11 | |
EPS (Basic) | Get a 7-Day Free Trial | -5.20 | -4.40 | -2.40 | -2.80 | -2.40 |
EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.
Poniard Pharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2010 is calculated as
Basic EPS (A: Dec. 2010 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Basic Average) |
= | (-30.051 | - | 0.736) | / | 1.172 | |
= | -26.27 |
Poniard Pharmaceuticals's Basic EPS for the quarter that ended in Sep. 2011 is calculated as
Basic EPS (Q: Sep. 2011 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Basic Average) |
= | (-3.771 | - | 0.048) | / | 1.498 | |
= | -2.55 |
EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2011 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Poniard Pharmaceuticals (OTCPK:PARD) EPS (Basic) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Thank you for viewing the detailed overview of Poniard Pharmaceuticals's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.
Michael S Perry | officer: President & CMO | C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155 |
Ron Martell | director, officer: Chief Executive Officer | PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111 |
Gary A Lyons | director | 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130 |
David R Stevens | director | 300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114 |
Gerald Phd Mcmahon | director | 300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114 |
Carl Goldfischer | director | 161 WEST 61ST STREET, NEW YORK NY 10022 |
Fred B Craves | director | 750 BATTERY ST, STE 600, SAN FRANCISCO CA 94111 |
Simon Nicholas J Iii | director, 10 percent owner | THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116 |
Gregory L Weaver | officer: Chief Financial Officer | 185 BERRY STREET, SUITE 6504, SAN FRANCISCO CA 94107 |
Kurt Wheeler | 10 percent owner | 801 GATEWAY BLVD, STE 410, SAN FRANCISCO CA 94080 |
Mpm Asset Management Investors 2005 Bviii Llc | 10 percent owner | C/O MPM ASSET MANAGEMENT, 111 HUNTINGTON AVENUE 31ST FLOOR, BOSTON MA 02199 |
Nicholas Galakatos | 10 percent owner | THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116 |
Dennis Henner | 10 percent owner | THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116 |
Michael Steinmetz | 10 percent owner | THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116 |
Luke Evnin | 10 percent owner | THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH STREET, BOSTON MA 02116 |
From GuruFocus
By gurufocus 10qk • 11-09-2010
By GuruFocus Research GuruFocus Editor • 08-22-2009
By gurufocus • 08-07-2009
By gurufocus 10qk • 11-06-2009
By gurufocus • 05-12-2009
By gurufocus • 04-06-2009
By gurufocus 10qk • 08-09-2010
By gurufocus 10qk • 05-10-2010
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.